☆ 4.6 Article

Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic body radiation therapy or systemic therapy alone

FRONTIERS IN ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

NRG/RTOG 1112: Randomized phase III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC).

Laura A. Dawson et al.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline

Smith Apisarnthanarax et al.

Summary: This guideline provides evidence-based recommendations for external beam radiation therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma, covering indications, techniques, outcomes, and emphasizing multidisciplinary care. Future studies should focus on defining the role of EBRT in the context of liver directed and systemic therapies.

PRACTICAL RADIATION ONCOLOGY (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

Maria Reig et al.

Summary: There have been significant advances in the treatment strategies for hepatocellular carcinoma since the last update in 2018. However, some interventions still lack sufficient data for clinical incorporation, and personalized clinical management requires consideration of multiple parameters.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial

Chris Parker et al.

Summary: This study suggests that radiotherapy to the prostate can improve overall survival for patients with newly diagnosed prostate cancer and low metastatic burden, without affecting their quality of life. However, it does not provide the same benefit for patients with high metastatic burden.

PLOS MEDICINE (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

Stereotactic body radiation therapy for hepatocellular carcinoma: From infancy to ongoing maturity

Shirley Lewis et al.

Summary: This review discusses the treatment modalities for hepatocellular carcinoma, including liver transplant, surgery, chemotherapy, and radiation therapy. The role of stereotactic body radiation therapy (SBRT) in the treatment of hepatocellular carcinoma has been refined and adopted in recent years, but there is currently a lack of high-quality level I evidence supporting its use.

JHEP REPORTS (2022)

添加到收藏夹

Review Oncology

Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer A Systematic Review and Meta-analysis

Eric J. Lehrer et al.

Summary: The meta-analysis shows that stereotactic ablative radiotherapy is relatively safe and clinically beneficial in patients with oligometastatic cancer, with low rates of toxic effects and acceptable survival rates. Further research is needed to validate these findings.

JAMA ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Stereotactic Radiotherapy for Hepatocellular Carcinoma, Radiosensitization Strategies and Radiation-Immunotherapy Combination

Luis A. Perez-Romasanta et al.

Summary: Radiotherapy is becoming increasingly important in the multidisciplinary treatment of liver cancer, particularly for patients who are not eligible for surgery. The optimal use of radiotherapy and its combination with other treatments for liver cancer are still unknown, but combining radiotherapy with chemotherapy, targeted therapy, nanoparticles, and immunotherapy shows promise in enhancing therapeutic outcomes. Further research is needed to evaluate and consolidate these promising therapies for liver cancer.

CANCERS (2021)

添加到收藏夹

Letter Oncology

Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines

A. Vogel et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Article Urology & Nephrology

Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study

Patrick Cheung et al.

Summary: SRT for oligoprogressive metastatic renal cell carcinoma (mRCC) lesions in patients on tyrosine kinase inhibitor (TKI) therapy showed high local control (LC) and delayed the need to change systemic therapy.

EUROPEAN UROLOGY (2021)

添加到收藏夹

Article Oncology

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

Robin Kate Kelley et al.

Summary: This study evaluated the treatment regimens for patients with hepatocellular carcinoma and found that all regimens were tolerable and clinically active, with the T300 + D regimen showing the most favorable benefit-risk profile. Early expansion of CD8+ lymphocytes was associated with treatment response across arms.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

Indications of external radiotherapy for hepatocellular carcinoma from updated clinical guidelines: Diverse global viewpoints

Sunmin Park et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial

David A. Palma et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial

David Ball et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Review Oncology

Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies

Chai Hong Rim et al.

RADIOTHERAPY AND ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study

Daniel R. Gomez et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Letter Oncology

Analysis of Toxic Effects With Antiangiogenic Agents Plus Stereotactic Body Radiation in Ultracentral Lung Tumors

Chunyu Wang et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma

Jens Ricke et al.

JOURNAL OF HEPATOLOGY (2019)

添加到收藏夹

Article Oncology

Combined Stereotactic Body Radiotherapy and Checkpoint Inhibition in Unresectable Hepatocellular Carcinoma: A Potential Synergistic Treatment Strategy

Chi-Leung Chiang et al.

FRONTIERS IN ONCOLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Projections of primary liver cancer to 2030 in 30 countries worldwide

Patricia C. Valery et al.

HEPATOLOGY (2018)

添加到收藏夹

Article Oncology

SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma

Pierce K. H. Chow et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer A Phase 2 Randomized Clinical Trial

Puneeth Iyengar et al.

JAMA ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Radiation-Induced Liver Disease and Modern Radiotherapy

Eugene J. Koay et al.

SEMINARS IN RADIATION ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial

Valerie Vilgrain et al.

LANCET ONCOLOGY (2017)

添加到收藏夹

Review Oncology

Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review

Stephanie G. C. Kroeze et al.

CANCER TREATMENT REVIEWS (2017)

添加到收藏夹

Review Oncology

Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy

Erqi L. Pollom et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)

添加到收藏夹

Article Oncology

Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen

Andrew B. Sharabi et al.

CANCER IMMUNOLOGY RESEARCH (2015)

添加到收藏夹

Review Oncology

Radiobiological mechanisms of stereotactic body radiation therapy and stereotactic radiation surgery

Mi-Sook Kim et al.

RADIATION ONCOLOGY JOURNAL (2015)

添加到收藏夹

Article Immunology

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

Eric A. Reits et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2006)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.